J. Wils

3.1k total citations · 1 hit paper
48 papers, 2.2k citations indexed

About

J. Wils is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, J. Wils has authored 48 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 10 papers in Surgery. Recurrent topics in J. Wils's work include Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (13 papers) and Pancreatic and Hepatic Oncology Research (11 papers). J. Wils is often cited by papers focused on Gastric Cancer Management and Outcomes (16 papers), Colorectal Cancer Treatments and Studies (13 papers) and Pancreatic and Hepatic Oncology Research (11 papers). J. Wils collaborates with scholars based in Netherlands, Belgium and France. J. Wils's co-authors include M.L. Couvreur, C.H.N. Veenhof, Tarek Sahmoud, Jean H. G. Klinkenbijl, Renée van Pel, Johannes Jeekel, Dionisio González, L T de Wit, A. Hennipman and Jean Arnaud and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Annals of Surgery.

In The Last Decade

J. Wils

46 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region

1999 918 citations Jean H. G. Klinkenbijl, Johannes Jeekel et al. Annals of Surgery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Wils Netherlands	20	1.7k	1.1k	760	490	487	48	2.2k
Robert Marsh United States	24	2.0k 1.2×	1.0k 1.0×	1.1k 1.4×	490 1.0×	462 0.9×	78	2.5k
Harald Schmalenberg Germany	17	2.3k 1.4×	1.6k 1.5×	1.3k 1.8×	573 1.2×	647 1.3×	46	3.1k
Osamu Kainuma Japan	20	1.6k 1.0×	789 0.7×	983 1.3×	310 0.6×	412 0.8×	80	2.1k
J. Fahlke Germany	10	2.0k 1.2×	924 0.9×	943 1.2×	543 1.1×	690 1.4×	28	2.3k
Francesco Minni Italy	30	1.7k 1.1×	887 0.8×	1.4k 1.9×	272 0.6×	557 1.1×	137	2.6k
L. Roll Germany	4	1.7k 1.1×	650 0.6×	736 1.0×	530 1.1×	665 1.4×	8	1.9k
Jörg Fahlke Germany	9	1.3k 0.8×	650 0.6×	732 1.0×	421 0.9×	394 0.8×	21	1.6k
Stephen A. Cullinan United States	15	1.4k 0.8×	703 0.7×	389 0.5×	297 0.6×	172 0.4×	25	1.8k
Marc E. Delclos United States	35	2.5k 1.5×	1.4k 1.3×	2.0k 2.7×	397 0.8×	397 0.8×	84	3.5k
Takeru Wakatsuki Japan	21	1.1k 0.7×	714 0.7×	531 0.7×	319 0.7×	162 0.3×	159	1.8k

Countries citing papers authored by J. Wils

Since Specialization

Citations

This map shows the geographic impact of J. Wils's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Wils with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Wils more than expected).

Fields of papers citing papers by J. Wils

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Wils. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Wils. The network helps show where J. Wils may publish in the future.

Co-authorship network of co-authors of J. Wils

This figure shows the co-authorship network connecting the top 25 collaborators of J. Wils. A scholar is included among the top collaborators of J. Wils based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Wils. J. Wils is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lalisang, Roy, Frans Erdkamp, C. J. Rodenburg, et al.. (2011). Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy. Breast Cancer Research and Treatment. 128(2). 437–445. 5 indexed citations

Hospers, Geke A.P., Michael Schaapveld, J.W.R. Nortier, et al.. (2006). Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Annals of Oncology. 17(3). 443–449. 29 indexed citations

Nitti, Donato, J. Wils, George Fountzilas, et al.. (2005). Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Annals of Oncology. 17(2). 262–269. 67 indexed citations

Littlewood, Timothy J., J.W.R. Nortier, Bernardo L. Rapoport, et al.. (2003). Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non‐platinum chemotherapy. Hematological Oncology. 21(4). 169–180. 33 indexed citations

Wagener, D. J. Th., J. Wils, T.C. Kok, et al.. (2002). Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with α-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial. European Journal of Cancer. 38(5). 648–653. 21 indexed citations

Hillen, H.F.P., Harry C. Schouten, Roy Lalisang, et al.. (2000). True. British Journal of Cancer. 82(12). 1914–1919. 5 indexed citations

Klinkenbijl, Jean H. G., Johannes Jeekel, Tarek Sahmoud, et al.. (1999). Adjuvant Radiotherapy and 5-Fluorouracil After Curative Resection of Cancer of the Pancreas and Periampullary Region. Annals of Surgery. 230(6). 776–776. 918 indexed citations breakdown →

Audisio, Riccardo A., Filippo de Braud, & J. Wils. (1998). Colorectal cancer. Critical Reviews in Oncology/Hematology. 27(2). 139–141. 1 indexed citations

Wils, J.. (1998). Treatment of gastric cancer. Current Opinion in Oncology. 10(4). 357–361. 27 indexed citations

10.

Lalisang, Roy, J. Wils, J Burghouts, et al.. (1997). Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer.. Journal of Clinical Oncology. 15(4). 1367–1376. 26 indexed citations

11.

Coombes, R. Charles, Judith M. Bliss, J. Wils, et al.. (1996). Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.. Journal of Clinical Oncology. 14(1). 35–45. 129 indexed citations

12.

Wymenga, A.N.M., Winette T.A. van der Graaf, J. Wils, et al.. (1996). A randomized, double-blind, multicentre study comparing daily 2 and 5 mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy. Annals of Oncology. 7(5). 505–510. 5 indexed citations

13.

Hoogenraad, W.J., A. Lusinchi, Babs G. Taal, et al.. (1996). Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: An EORTC GITCCG study. European Journal of Cancer. 32(8). 1310–1313. 16 indexed citations

14.

Wils, J., T.C. Kok, D. J. Th. Wagener, J. Selleslags, & N. Duez. (1993). Activity of cisplatin in adenocarcinoma of the pancreas. European Journal of Cancer. 29(2). 203–204. 63 indexed citations

15.

Wils, J., et al.. (1992). Intraperitoneal Cisplatin in the Treatment of Refractory or Recurrent Advanced Ovarian Carcinoma. Oncology. 49(6). 442–444. 2 indexed citations

16.

Wils, J.. (1991). Perspectives in chemotherapy of advanced gastric cancer. Anti-Cancer Drugs. 2(2). 133–138. 2 indexed citations

17.

Wils, J. & Jan Smeets. (1991). Phase II Study of Cyclophosphamide (C), Epirubicin (E), Oncovin (O), Prednisone (P), Methotrexate (M) + Leucovorin and Bleomycin (B) (CEOP-MB) in Intermediate and High Grade Non-Hodgkin Lymphomas. Journal of Chemotherapy. 3(4). 260–263. 2 indexed citations

18.

Wils, J.. (1988). Treatment of Pancreatic Carcinoma: Therapeutic Nihilism?. Recent results in cancer research. 110. 87–94. 3 indexed citations

19.

Blijham, G.H., et al.. (1985). Primary chemotherapy in cancer medicine. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 142(6). 1077–80. 32 indexed citations

20.

Wils, J. & P W Kloppenborg. (1970). Recurrence of hyperthyroidism shortly after return of normal suppressibility by triiodothyronine.. BMJ. 3(5718). 327–327. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact